This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group
Blood Cancer Journal Open Access 09 March 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420.
Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 2007; 109: 3489–3495.
Saccaro S, Fonseca R, Veillon DM, Cotelingam J, Nordberg ML, Bredeson C et al. Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol 2005; 78: 288–294.
Gertz M . Managing plasma cell leukemia. Leuk Lymphoma 2007; 48: 5–6.
Blade J, Kyle RA . Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am 1999; 13: 1259–1272.
Avet-Loiseau H, Daviet A, Brigaudeau C, Callet-Bauchu E, Terré C, Lafage-Pochitaloff M et al. Cytogenetic, interphase and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia. A study of 40 cases at diagnosis. Blood 2001; 97: 822–825.
Esparis-Ogando A, Alegre A, Aguado B, Mateo G, Gutiérrez N, Bladé J et al. Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer 2005; 114: 665–667.
Musto P, Rossini F, Gay F, Pitini V, Guglielmelli T, D’Arena G et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer 2007; 109: 2285–2290.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Avet-Loiseau, H., Roussel, M., Campion, L. et al. Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience. Leukemia 26, 158–159 (2012). https://doi.org/10.1038/leu.2011.176
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2011.176
This article is cited by
-
Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era
Leukemia (2020)
-
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias
Leukemia (2018)
-
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group
Blood Cancer Journal (2018)
-
Risk Stratification in Multiple Myeloma
Current Hematologic Malignancy Reports (2016)
-
Primary Plasma Cell Leukemia: Identity Card 2016
Current Treatment Options in Oncology (2016)